News stories about Catalent (NYSE:CTLT) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catalent earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5396907271226 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of research analysts have commented on CTLT shares. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, March 9th. KeyCorp upgraded shares of Catalent from a “sector weight” rating to an “overweight” rating and set a $48.00 price objective on the stock in a research note on Wednesday, March 28th. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, June 5th. UBS Group upgraded shares of Catalent from a “market perform” rating to an “outperform” rating in a research note on Wednesday, March 21st. Finally, Raymond James upgraded shares of Catalent from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a research note on Wednesday, March 21st. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $45.67.

Shares of Catalent stock traded up $1.28 on Thursday, reaching $41.54. 783,100 shares of the stock were exchanged, compared to its average volume of 830,790. The company has a quick ratio of 1.78, a current ratio of 2.18 and a debt-to-equity ratio of 2.53. Catalent has a 1-year low of $33.42 and a 1-year high of $47.87. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of 30.77, a price-to-earnings-growth ratio of 2.11 and a beta of 1.50.

Catalent (NYSE:CTLT) last issued its earnings results on Tuesday, May 1st. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.06. Catalent had a net margin of 2.62% and a return on equity of 21.76%. The company had revenue of $627.90 million for the quarter, compared to analyst estimates of $610.47 million. During the same period in the prior year, the business posted $0.38 earnings per share. The firm’s revenue for the quarter was up 17.9% compared to the same quarter last year. equities research analysts anticipate that Catalent will post 1.55 EPS for the current year.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.